Glenmark pharmaceuticals on Saturday launched anti-viral drug favipiravir for treatment of mild-to-moderate covid-19 cases after it received the Indian drug regulator’s approval.

It will be available under the brand name FabiFlu as a prescription based medicine for Rs 103/ tablet and the recommended dose is 1800 mg two times in a day on DAY 1 and remaining 13 days the dosage should be of 800 mg.

Glenmark received the approval for manufacturing & marketing Favipiravir from the drug controller general of India on Friday.

Favipiravir is backed by strong clinical evidence, showing encouraging result in patient with mild to moderate Covid-19. It offers broad spectrum RNA virus coverage with clinical improvement noted in 20-90 plus age group.

The best news is Favipiravir could be used for covid-19 patient with comorbid condition, like diabetes & heart disease; the company said and added, it would offer rapid reduction in viral load within four days, & faster symptomatic and radiological improvement.

Glenmark was the first company in India to receive the drug regulator’s approval to conduct phase-3 clinical trial of Favipiravir antiviral tablets for covid-19 patients.  Favipiravir is a generic version of Avigan of Fujifilm Toyama chemical, Japan, a subsidiary of Fujifilm Toyama chemical, japan, a subsidiary of Fujifilm Corporation